0.32
-0.0193(-5.74%)
Currency In USD
| Previous Close | 0.34 |
| Open | 0.33 |
| Day High | 0.34 |
| Day Low | 0.32 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 5.82M |
| Average Volume | 27.16M |
| Market Cap | 16.17M |
| PE | -0.11 |
| EPS | -2.78 |
| Moving Average 50 Days | 0.38 |
| Moving Average 200 Days | 0.96 |
| Change | -0.02 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of July 16, 2025 at a share price of $0.317. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $9.78 as of July 16, 2025 at a share price of $0.317.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (G
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
GlobeNewswire Inc.
Jul 10, 2025 11:30 AM GMT
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company’s CNSide Cerebros
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire Inc.
Jul 08, 2025 11:30 AM GMT
Substantial clinical need expected to facilitate rapid overall trial enrollmentHOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiothera